1. No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.
- Author
-
Maugham ML, Seim I, Thomas PB, Crisp GJ, Shah ET, Herington AC, Brown KA, Gregory LS, Nelson CC, Jeffery PL, and Chopin LK
- Subjects
- Animals, Blood Glucose, Cell Line, Tumor, Diet, High-Fat, Ghrelin therapeutic use, Heterografts, Homeodomain Proteins genetics, Humans, Hyperinsulinism metabolism, Male, Mice, Mice, Knockout, Obesity metabolism, Prostatic Neoplasms complications, Prostatic Neoplasms metabolism, Ghrelin pharmacology, Homeodomain Proteins metabolism, Hyperinsulinism complications, Obesity complications, Prostatic Neoplasms drug therapy
- Abstract
Ghrelin is a peptide hormone which, when acylated, regulates appetite, energy balance and a range of other biological processes. Ghrelin predominately circulates in its unacylated form (unacylated ghrelin; UAG). UAG has a number of functions independent of acylated ghrelin, including modulation of metabolic parameters and cancer progression. UAG has also been postulated to antagonise some of the metabolic effects of acyl-ghrelin, including its effects on glucose and insulin regulation. In this study, Rag1-/- mice with high-fat diet-induced obesity and hyperinsulinaemia were subcutaneously implanted with PC3 prostate cancer xenografts to investigate the effect of UAG treatment on metabolic parameters and xenograft growth. Daily intraperitoneal injection of 100 μg/kg UAG had no effect on xenograft tumour growth in mice fed normal rodent chow or 23% high-fat diet. UAG significantly improved glucose tolerance in host Rag1-/- mice on a high-fat diet, but did not significantly improve other metabolic parameters. We propose that UAG is not likely to be an effective treatment for prostate cancer, with or without associated metabolic syndrome., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2018
- Full Text
- View/download PDF